Drug Safety Evaluation of Traditional Unani Medicine Pharmacovigilance Systems

Abstract

The integration of pharmacovigilance systems into traditional Unani medicine is critical for ensuring drug safety and effective therapeutic outcomes. This review synthesizes current literature on the epidemiology, risk factors, pathophysiology, and clinical features associated with adverse drug reactions (ADRs) in Unani medicine, while evaluating diagnostic, management, and monitoring strategies. Emphasis is placed on the mechanisms of toxicity, evidence-based pharmacovigilance models, and the incorporation of emerging guidelines, with the goal of enhancing the safety profile of Unani pharmacotherapies in routine clinical practice.

Introduction

Traditional Unani medicine, rooted in Greco-Arabic medical traditions, remains widely practiced across South Asia and the Middle East. Despite its popularity and a long history of empirical use, systematic evaluation of drug safety within Unani pharmacovigilance frameworks is comparatively nascent. With rising global utilization, the potential for adverse drug reactions, herb-drug interactions, and toxicity necessitates a robust, evidence-based approach to pharmacovigilance. This article reviews contemporary advances in Unani pharmacovigilance, addressing key challenges and proposing integrative models for improving patient safety.

Epidemiology / Disease Burden

The global burden of adverse events from traditional medicines, including Unani, is increasingly recognized. Studies estimate that 5-10% of hospital admissions in developing countries are associated with ADRs, including those linked to herbal and natural medicines. In India, where Unani medicine forms a key pillar of the AYUSH healthcare system, underreporting of ADRs is a major concern, with pharmacovigilance centers receiving significantly fewer reports compared to allopathic systems. This underlines a gap in awareness, reporting infrastructure, and systematic monitoring within the Unani sector.

Pathophysiology

Unani medicines are composed of complex herbal, mineral, and animal-derived substances, each with unique pharmacodynamic and pharmacokinetic profiles. The pathophysiology of ADRs in Unani medicine can involve direct toxic effects, immunologically mediated hypersensitivity, idiosyncratic reactions, and cumulative toxicity from prolonged use. For example, ingredients such as mercury, arsenic, and lead, occasionally used in classical formulations, pose risks of nephrotoxicity, neurotoxicity, and hepatotoxicity. Furthermore, interactions with conventional drugs can alter metabolic pathways, leading to unforeseen adverse outcomes.

Risk Factors

Several risk factors potentiate the occurrence of ADRs in Unani medicine. These include patient-specific factors such as age, comorbidities (especially hepatic and renal impairment), polypharmacy, genetic polymorphisms affecting drug metabolism, and pregnancy. Preparation-related factors, such as improper identification of raw materials, contamination, incorrect dosage, and lack of standardization, further contribute to safety risks. Additionally, self-medication and unsupervised use are prevalent, particularly in rural and peri-urban areas.

Clinical Features

Clinical manifestations of Unani drug-related ADRs range from mild gastrointestinal disturbances (nausea, vomiting, diarrhea) to severe systemic effects such as hepatotoxicity, nephrotoxicity, anaphylaxis, and cutaneous reactions. Chronic toxicity may present as insidious organ dysfunction, often detected only upon targeted investigation. Recent case series have highlighted instances of acute liver injury and chronic kidney disease associated with long-term Unani medication use, underscoring the need for vigilant clinical monitoring.

Diagnosis

Diagnosis of ADRs in Unani medicine requires a high index of suspicion, comprehensive patient history, and awareness of commonly implicated formulations. Laboratory evaluation (liver and renal function tests, hematologic parameters) and causality assessment tools (e.g., WHO-UMC scale, Naranjo algorithm) have been adapted for traditional medicine contexts. Analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry are increasingly employed to detect adulterants and confirm the presence of toxic constituents.

Treatment & Management

Management of ADRs typically involves immediate discontinuation of the suspected Unani product, symptomatic support, and organ-specific interventions. In severe cases, hospitalization and intensive care may be required. Patient education, routine monitoring of laboratory parameters, and regular follow-up are essential components of a comprehensive management plan. Collaborative care with allopathic practitioners can facilitate early identification and mitigation of drug interactions and adverse events.

Recent Advances / Emerging Therapies

Recent years have witnessed the development of specialized pharmacovigilance centers dedicated to traditional medicine, including Unani. The Indian Pharmacopoeia Commission and the National Pharmacovigilance Program for AYUSH have introduced standardized reporting forms, electronic databases, and practitioner training programs. Advances in biomarker discovery, toxicogenomics, and pharmacogenetics hold promise for individualized risk stratification. Additionally, efforts to standardize Unani drug formulations and implement good manufacturing practices are improving product safety profiles.

Guideline Recommendations

Guidelines from the World Health Organization (WHO) and the Ministry of AYUSH emphasize the integration of pharmacovigilance into traditional healthcare systems. Key recommendations include mandatory ADR reporting, routine safety monitoring, practitioner education on pharmacovigilance principles, and public awareness campaigns. The adoption of international best practices—such as causality assessment, periodic safety update reports, and risk management plans—are encouraged to align Unani medicine with global drug safety standards.

Conclusion

Robust pharmacovigilance systems are indispensable for ensuring the safety of Unani medicines in contemporary clinical settings. Through the integration of modern diagnostic tools, evidence-based guidelines, and interdisciplinary collaboration, Unani pharmacovigilance can evolve to meet the needs of both practitioners and patients. Ongoing research, infrastructural development, and a culture of safety reporting will be crucial in minimizing ADRs and maximizing the therapeutic potential of this centuries-old medical tradition.